Amazon Biotech, Inc. (OTC BB: AMZB) today announced that it has submitted to the FDA its protocol to test AMZ0026 as an antiviral and immuno-modulating agent in HAART-treated HIV subjects. The current study design includes 32 non-symptomatic HIV subjects who are currently treated with Highly Active Anti-Retroviral Therapy (HAART), whereby 50% of the subjects will be continuing their current HAART regimen without change, and 50% will receive AMZ0026 along with their current HAART regimen. The study will entail six months treatment with monitoring of T Cell increases, HIV plasma viral load decreases and improvements in quality of life.
